News & Events about Rocket Pharmaceuticals Inc.
Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT Get Rating) have received a consensus rating of Moderate Buy from the thirteen brokerages that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation ...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces updates from the Company's end-of-Phase 1 meeting with the U.S. Food and...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces positive clinical data from its lentiviral (LV)-based gene therapy...
Rocket Pharmaceuticals (NASDAQ:RCKT Get Rating) had its price target lowered by SVB Leerink from $56.00 to $54.00 in a report issued on Tuesday, MarketBeat.com reports. SVB Leerink currently has an outperform rating on the biotechnology companys stock. SVB Leerink also issued estimates for Rocket ...
Business Wire
2 months ago
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that Gaurav Shah, M.D., Chief Executive Officer, will participate in a...